Publications by authors named "Maria de Los Dolores Fenor De La Maza"
Article Synopsis
- * BCL2, an anti-apoptotic protein, is upregulated in these aggressive prostate cancers, which presents a potential target for therapy and highlights the importance of studying its expression in metastatic CRPC (mCRPC).
- * Research shows that BCL2 is more prevalent in AR-negative mCRPC and is linked to poorer survival outcomes; also, its regulation involves DNA methylation and a transcription factor called ASCL1, suggesting the need for combination therapies to improve treatment efficacy.
BACKGROUNDClinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The current study reports on RNASEH2B protein loss in advanced prostate cancer and its association with RB1 protein loss, clinical outcome, and clonal dynamics during treatment with PARP inhibition in a prospective clinical trial.
View Article and Find Full Text PDFArticle Synopsis
- BAG-1L is a key protein that enhances the androgen receptor's function, playing a role in the progression of prostate cancer.
- Researchers developed a new antibody specific to BAG-1L to study its expression in various prostate cancer stages and breast cancer tissues.
- Higher BAG-1L levels were found in metastases of castration-resistant prostate cancer compared to untreated cases, but no correlation was found between BAG-1L levels and patient outcomes or responses to treatments, highlighting some limitations in the study's findings.
Article Synopsis
- Germline mutations in the ATM gene, found in 0.5-1% of the population, are linked to a higher risk of aggressive prostate cancer (PC), but their clinical features are not well understood.
- This study focused on patients with advanced metastatic castration-resistant prostate cancer (CRPC) who had these mutations identified through initial tumor DNA sequencing, collecting data on demographic details, family history, and clinical outcomes.
- Among the seven identified patients (0.6%), most had a family history of various cancers, with a median overall survival from diagnosis of 7.1 years, indicating that the presence of these mutations could be significant in understanding PC progression and patient outcomes.
Objectives: Investigate the laboratory, imaging and procedural factors that are associated with a tumour-positive and/or NGS-feasible CT-guided sclerotic bone lesion biopsy result in cancer patients.
Methods: In total, 113 CT-guided bone biopsies performed in cancer patients by an interventional radiologist in one institution were retrospectively reviewed. Sixty-five sclerotic bone biopsies were eventually included and routine blood parameters and tumour marker levels were recorded.
The bromodomain and extraterminal (BET) family of chromatin reader proteins bind to acetylated histones and regulate gene expression. The development of BET inhibitors (BETi) has expanded our knowledge of BET protein function beyond transcriptional regulation and has ushered several prostate cancer (PCa) clinical trials. However, BETi as a single agent is not associated with antitumor activity in patients with castration-resistant prostate cancer (CRPC).
View Article and Find Full Text PDFMultiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing.
Eur Radiol
July 2022
Objectives: To evaluate whether multiparametric bone MRI (mpBMRI) utilising a combination of DWI signal, ADC and relative fat-fraction (rFF) can identify bone metastases, which provide high diagnostic biopsy yield and next-generation genomic sequencing (NGS) feasibility.
Methods: A total of 150 CT-guided bone biopsies performed by interventional radiologists (3/2013 to 2/2021) at our centre were reviewed. In 43 patients, contemporaneous DWI and rFF images, calculated from 2-point T1w Dixon MRI, were available.
A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer.
Annu Rev Pharmacol Toxicol
January 2022
Owing to the development of multiple novel therapies, there has been major progress in the treatment of advanced prostate cancer over the last two decades; however, the disease remains invariably fatal. Androgens and the androgen receptor (AR) play a critical role in prostate carcinogenesis, and targeting the AR signaling axis with abiraterone, enzalutamide, darolutamide, and apalutamide has improved outcomes for men with this lethal disease. Targeting the AR and elucidating mechanisms of resistance to these agents remain central to drug development efforts.
View Article and Find Full Text PDFTargeting the androgen receptor by depriving testosterone with gonadotropin-releasing hormone agonists or antagonists, or surgical castration, has been the backbone of metastatic prostate cancer treatment. Although most prostate cancers initially respond to androgen deprivation, metastatic castration-resistant prostate cancer evolves into a heterogeneous disease with diverse drivers of progression and mechanisms of therapeutic resistance. Development of castrate resistance phenotype is associated with lethality despite the recent noteworthy strides gained via increase in therapeutic options.
View Article and Find Full Text PDFArticle Synopsis
- Prostate cancer is a serious illness that causes many men to die, and it's often linked to problems in DNA repair in about 25% of patients with advanced cancer.
- New treatments like PARP inhibitors and immunotherapy are being tested to help these patients, especially those with specific genetic mutations like BRCA.
- Recent studies show that while some treatments are working well for certain groups, there are challenges in predicting who will benefit from them, and finding solutions to these problems is really important for better care in the future.